Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3548–3550.

https://doi.org/10.1182/blood-2022-170228

Published: 2022

Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta

Blood (2022) 140 (Supplement 1): 7070–7071.

https://doi.org/10.1182/blood-2022-157927

Published: 2022

Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi

Blood (2022) 140 (Supplement 1): 3865–3867.

https://doi.org/10.1182/blood-2022-166407

Published: 2022

Journal Articles

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 890.

https://doi.org/10.1182/blood-2021-148536

Published: 2021

Journal Articles

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Jian Kang, Hsiling Chiu, Archana Mukhopadhyay, Krista Wollerman, Michael Pourdehnad, Patrick Hagner, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2021-153907

Published: 2021

Journal Articles

Low Exposure Extended Dosing Mimicking Clinical Exposures of the Oral Formulation of Azacitidine Results in a Sustained Hypomethylation and Targets Leukemic Stem Cells

Danny V Jeyaraju, Maryam Alapa, Ann Polonskaia, Alberto Risueño, Aarif Ahsan, Chao Wang, Prakash Subramanyam, Jammula Sriganesh, Amit Anand, Gaurav Jain, Madhusudhan Reddy, Kaushik Ghosh, Charalampos Kyriakopoulos, Nathalie Lailler, Christopher Hartl, Daniel Lopes de Menezes, Patrick Hagner, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2021-153523

Published: 2021

Journal Articles

Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing

Yumi Nakayama, Hsiling Chiu, Rama K. Narla, Arvind Shakya, Jim Gamez, Isobelle Wall, Despoina Papazoglou, Benedetta Apollonio, Alan G. Ramsay, Patrick Hagner, Anita K Gandhi

Blood (2021) 138 (Supplement 1): 718.

https://doi.org/10.1182/blood-2021-153063

Published: 2021

Journal Articles

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, Tiziana Civardi, Jessica Katz, Paulo Maciag, Patrick Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2021-153994

Published: 2021

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta, Daniel Lopes de Menezes, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-137606

Published: 2020

Journal Articles

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD

Blood (2016) 128 (22): 1592.

https://doi.org/10.1182/blood.V128.22.1592.1592

Published: 2016

Journal Articles

Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity

Blood (2015) 126 (23): 821.

https://doi.org/10.1182/blood.V126.23.821.821

Published: 2015

Journal Articles

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

Hsiling Chiu, Patrick Hagner, PhD, Michael Pourdehnad, MD, Thomas Daniel, Rajesh Chopra, Anke Klippel, Christian Klein, PhD, Anjan Thakurta, Anita K. Gandhi, PhD

Blood (2015) 126 (23): 4007.

https://doi.org/10.1182/blood.V126.23.4007.4007

Published: 2015

Journal Articles

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Cecilia Carpio, MD, Loïc Ysebaert, MDPhD, Raúl Cordoba, MD, Armando Santoro, MD, José Antonio López-Martín, MD, Juan Manuel Sancho, MD PhD, Carlos Panizo, PhD, Mecide Meric Gharibo, MD, Drew W Rasco, MD, Anne-Marie Stoppa, MD, Sylvia Damian, MD, Xin Wei, Patrick Hagner, PhD, Kristen Hege, Soraya Carrancio, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Vincent Ribrag, MD

Blood (2015) 126 (23): 1494.

https://doi.org/10.1182/blood.V126.23.1494.1494

Published: 2015

Journal Articles

CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse

Benedetta Apollonio, PhD, Mariam Fanous, BSc, MSc, Mohamed-Reda Benmebarek, BSc, MRes, Stephen Devereux, FRCP, FRCPath, PhD, Patrick Hagner, PhD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD, Piers E. Patten, BSc, MRCP, MRCPath, PhD, Alan G. Ramsay, PhD

Blood (2015) 126 (23): 1738.

https://doi.org/10.1182/blood.V126.23.1738.1738

Published: 2015

Journal Articles

CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

Blood (2015) 126 (23): 2704.

https://doi.org/10.1182/blood.V126.23.2704.2704

Published: 2015

Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD

Blood (2014) 124 (21): 3035.

https://doi.org/10.1182/blood.V124.21.3035.3035

Published: 2014

Journal Articles

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Vincent Ribrag, MD, Silvia Damien, MD, Mecide Gharibo, MD, Mercede Gironella, MD, Armando Santoro, MD, Drew W Rasco, MD, William Edenfield, MD, Xin Wei, PhD, Angela James, PhD, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Jorge F. DiMartino, MD PhD, Michael Pourdehnad, MD, Anne-Marie Stoppa, MD

Blood (2014) 124 (21): 3500.

https://doi.org/10.1182/blood.V124.21.3500.3500

Published: 2014

Journal Articles

Dominant-Negative Inhibition of MCT-1 Oncogene Attenuates a Malignant Phenotype through Translational Repression.

Patrick Hagner, MS, Krystyna Mazan-Mamczarz, PhD, Sharon Corl, BS, Ron B. Gartenhaus, MD

Blood (2007) 110 (11): 4168.

https://doi.org/10.1182/blood.V110.11.4168.4168

Published: 2007

NARROW

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Low Exposure Extended Dosing Mimicking Clinical Exposures of the Oral Formulation of Azacitidine Results in a Sustained Hypomethylation and Targets Leukemic Stem Cells

Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse

CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Dominant-Negative Inhibition of MCT-1 Oncogene Attenuates a Malignant Phenotype through Translational Repression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only